Accenture vs Amgen: Revenue, Profit and Business Model
Accenture reported $69.7B of revenue in FY2025 and $7.7B of net income. Amgen reported $36.8B of revenue in FY2025 and $7.7B of net income.
Latest financial snapshot
Financial summary
Accenture
Accenture's fiscal year ends August 31. Revenue rose from $34.80B in FY2016 to $69.67B in FY2025, and net income attributable to Accenture plc rose from $4.11B to $7.68B over the same period. FY2025 brought $80.62B in new bookings, $10.87B of free cash flow, GAAP diluted EPS of $12.15 and $8.3B returned to shareholders through dividends and buybacks. Spending on acquisitions was $6.58B in FY2024 and $1.47B in FY2025. In Q3 FY2026 (to May 31, 2026) revenue was $18.72B, up 6% in U.S. dollars and 3% in local currency, and full-year FY2026 results are due on October 1, 2026.
Amgen
Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.
Revenue and profit by year
Accenture
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $69.7B | $7.7B | 11.0% | +7.4% | Source |
| FY2024 | $64.9B | $7.3B | 11.2% | +1.2% | Source |
| FY2023 | $64.1B | $6.9B | 10.7% | +4.1% | Source |
| FY2022 | $61.6B | $6.9B | 11.2% | +21.9% | Source |
| FY2021 | $50.5B | $5.9B | 11.7% | +14.0% | Source |
| FY2020 | $44.3B | $5.1B | 11.5% | +2.6% | Source |
| FY2019 | $43.2B | $4.8B | 11.1% | +5.4% | Source |
| FY2018 | $41B | $4.1B | 9.9% | +13.3% | Source |
| FY2017 | $36.2B | $3.4B | 9.5% | +4.0% | Source |
| FY2016 | $34.8B | $4.1B | 11.8% | — | Source |
Amgen
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $36.8B | $7.7B | 21.0% | +10.0% | Source |
| FY2024 | $33.4B | $4.1B | 12.2% | +18.6% | Source |
| FY2023 | $28.2B | $6.7B | 23.8% | +7.1% | Source |
| FY2022 | $26.3B | $6.6B | 24.9% | +1.3% | Source |
| FY2021 | $26B | $5.9B | 22.7% | +2.2% | Source |
| FY2020 | $25.4B | $7.3B | 28.6% | +8.8% | Source |
| FY2019 | $23.4B | $7.8B | 33.6% | -1.6% | Source |
| FY2018 | $23.7B | $8.4B | 35.3% | +3.9% | Source |
| FY2017 | $22.8B | $2B | 8.7% | -0.6% | Source |
| FY2016 | $23B | $7.7B | 33.6% | — | Source |
Where the revenue comes from
Accenture
- Consulting
$35.11B in FY2025 revenue
Consulting includes strategy, technology consulting, systems integration, cloud migration, data and AI programs, and large transformation projects.
- Managed Services
$34.57B in FY2025 revenue
Managed Services includes application management, infrastructure operations, business process services, finance operations, customer operations, and other long-term outsourced work.
- AI, Data, and Digital Core
Reported across consulting and managed services
Accenture embeds AI, data, cybersecurity, cloud, enterprise platforms, and digital core modernization into client transformation programs.
- Song, Supply Chain, Engineering, and Talent
Reported across service lines
These capabilities cover customer experience, commerce, design, marketing technology, product engineering, supply chain, workforce transformation, and change management.
Amgen
- U.S. product sales
~70% of total revenues
United States product sales were US$25.66 billion in fiscal 2025, 73% of the US$35.15 billion product sales total and about 70% of total revenues. The largest domestic contributors were Prolia (US$2.98 billion), Enbrel (US$2.20 billion), Otezla (US$1.84 billion), Tepezza (US$1.76 billion), Repatha (US$1.66 billion), Evenity (US$1.60 billion) and Tezspire (US$1.48 billion). Access depends on formulary placement with the large pharmacy benefit managers and on Medicare and Medicaid reimbursement.
- International product sales
~26% of total revenues
Product sales outside the United States were US$9.49 billion in fiscal 2025, 27% of product sales. The largest were Repatha (US$1.35 billion), Aranesp (US$973 million), XGEVA (US$729 million), Vectibix (US$571 million) and Amgevita (US$549 million). Prices are generally lower than in the United States because of government reference pricing and national formulary negotiation.
- Biosimilars
~8% of total revenues
Biosimilars sit inside product sales and generated about US$3.0 billion in fiscal 2025: Mvasi (bevacizumab) US$771 million, Pavblu (aflibercept) US$700 million, Amjevita and Amgevita (adalimumab) US$597 million, Wezlana and Wezenla (ustekinumab) US$273 million, and US$683 million across the smaller biosimilars reported within other products. Amjevita sales fell 22% year over year, so segment growth now comes from the newer launches.
- Rare disease portfolio acquired with Horizon
~13% of total revenues
Also inside product sales, the medicines acquired with Horizon Therapeutics produced about US$4.6 billion in fiscal 2025: Tepezza US$1.90 billion, Krystexxa US$1.34 billion, Uplizna US$655 million and the ultra-rare products US$719 million. Uplizna grew 73% after approvals in IgG4-related disease and generalized myasthenia gravis, while the ultra-rare group fell 5% as Ravicti met generic competition.
- Other revenues
~4% of total revenues
Other revenues, mainly royalties, license income and corporate partner payments, were US$1.60 billion in fiscal 2025, the difference between US$36.75 billion of total revenues and US$35.15 billion of product sales. The line carries high margins but is not a growth priority.
Business model and strategy
Accenture
How it makes money
Accenture sells professional services to large companies and governments. Consulting revenue ($35.11B in FY2025) comes from strategy, technology implementation, cloud migration and data and AI projects. Managed services revenue ($34.57B) comes from multi-year contracts to run applications, infrastructure and business processes such as finance or customer operations.
Growth strategy
Accenture grows through a mix of organic services and frequent acquisitions. It spent $6.58B on businesses and investments in FY2024 and $1.47B in FY2025, and in 2026 announced its largest recent deals: Faculty in the UK and the $1.2B Ookla agreement.
Competitive advantage
Accenture can take a client from strategy work through systems implementation and then run the resulting systems or processes under multi-year managed services contracts; in FY2025 managed services was $34.57B of its $69.67B revenue.
Amgen
How it makes money
Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price.
Growth strategy
Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year.
Competitive advantage
Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989.
Questions about Accenture vs Amgen
Which company has higher revenue — Accenture PLC or Amgen Inc.?
Accenture PLC reported $69.7B (FY2025), while Amgen Inc. reported $36.8B (FY2025). By last reported revenue, Accenture PLC is the larger business, with Amgen Inc. reporting a smaller revenue base.
What is the market cap of Accenture PLC vs Amgen Inc.?
Accenture PLC's market capitalisation stands at $110.7B, while Amgen Inc.'s is $228.2B. Amgen Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Accenture PLC.
Which is more financially efficient — Accenture PLC or Amgen Inc.?
Accenture PLC generates $87k / employee in revenue per employee, while Amgen Inc. generates $1.17M / employee. Amgen Inc. shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Accenture PLC and Amgen Inc. make money?
Accenture PLC and Amgen Inc. generate revenue in fundamentally different ways. Accenture PLC: Accenture sells professional services to large companies and governments. Amgen Inc.: Amgen operates a high-risk, high-reward biopharmaceutical business model.
Which company is valued higher relative to revenue — Accenture PLC or Amgen Inc.?
On a price-to-sales (P/S) basis, Accenture PLC trades at 1.6x P/S and Amgen Inc. at 6.2x P/S. Amgen Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Accenture PLC. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Accenture PLC bigger than Amgen Inc.?
By last reported revenue, Accenture PLC ($69.7B (FY2025)) is the larger company compared to Amgen Inc. ($36.8B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Accenture vs Amgen overview